Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102

Basit Öğe Kaydı
dc.authorid0000-0001-9717-4581
dc.contributor.authorHacıoğlu, Muhammet Bekir
dc.contributor.authorKöstek, Osman
dc.contributor.authorKurt, Nazmi
dc.contributor.authorKüçükarda, Ahmet
dc.contributor.authorGökyer, Ali
dc.contributor.authorUstabaşıoğlu, Fethi Emre
dc.contributor.authorKarataş, Fatih
dc.contributor.authorTunçbilek, Nermin
dc.contributor.authorUzuno?lu, Sernaz
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorErdoğan, Bülent
dc.date.accessioned2019-12-27T17:21:14Z
dc.date.available2019-12-27T17:21:14Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments and prognostic significance in the patients with metastatic colorectal cancer (mCRC). Methods: A total of 36 mCRC patients, who received regorafenib or TAS-102 in the third-line and subsequent settings were assessed in the analysis. SMM changes were assessed with CT scans findings, and they were categorized into two groups as SMM-loss (SMM decrease ?2%) and SMM-stable (SMM change <2%). Results: The SMM change after regorafenib therapy was significantly worse compared with TAS-102 therapy (p=0.001). The median overall survival (OS) was longer in SMM-stable group than in SMM-loss group (12.8 months; 95%CI:9.8-15.7) vs. 6.4 months; 95%CI:5.2-7.7, respectively;p=0.04). Cox regression analysis showed that SMM loss was independent prognostic indicator for OS (HR, 2.87; 95%CI: 1.07-7.42, p=0.03). Conclusion: Although patients who received regorafenib had more SMM loss than those who received TAS-102, there was no difference in OS between drugs.
dc.identifier.citationHacıoğlu, M. B., Köstek, O., Kurt, N., Küçükarda, A., Gökyer, A., Ustabaşıoğlu, F. E. ... Erdoğan, B. (2019). Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102. Journal of B.U.ON., 24(5), 2198-2204.
dc.identifier.endpage2204
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue5
dc.identifier.scopusqualityQ3
dc.identifier.startpage2198
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4786
dc.identifier.volume24
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherZerbinis Publications
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMetastatic Colorectal Cancer
dc.subjectRegorafenib
dc.subjectTAS- 102
dc.subjectSarcopenia
dc.subjectSkeletal Muscle Mass
dc.titleComparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bilici, Ahmet.pdf
Boyut:
924.44 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu